Computer-Aided Drug Discovery Market Expected to Reach $7.5 Billion by 2030—Allied Market Research

According to a new report published by Allied Market Research, titled, “Computer-Aided Drug Discovery Market," The computer-aided drug discovery market size was $2.9 billion in 2021, and is estimated to reach $7.5 billion by 2030, growing at a CAGR of 11.48% from 2022 to 2030.

In the world of drug development, CADD is an effective tool for identifying potential therapeutic compounds. Computer-aided Drug Design (CADD) is a drug design technique used in medicinal chemistry. The method use software to create several chemical structures with minor modifications to a single medication structure that has already been shown to be therapeutically efficacious. CADD's main goal is to screen, optimise, and analyse the compound's activity against the target. It is a multidisciplinary method that is used by both academic institutions and commercial pharmaceutical firms to improve efficacy while minimising or eliminating negative effects. It is now the best option for elevated screening, which is widely used in drug development.

Growing research and development activities in the field of drugs and vaccines is likely to accelerate computer aided drug discovery market share growth. CADD techniques/tools have been used in almost every stage of the drug development pipeline because of their ability to accelerate hit identification, strike to lead, and result enhancement. Over the last two decades, advances in computer-aided drug design at the technique/tool level, combined with the development of computational power, have enabled the scientific community to begin producing disease-oriented fast and reliable remedies at a low cost and in a manageable time frame.

Computer aided drug discovery market size is likely to accelerate in the coming few years owing to incorporation of advanced technology in CADD. The merging of Artificial Intelligence and Machine Learning with structure-based approaches has emerged as a powerful new tool for drug development. Perhaps the scientific community will have to overcome the challenges posed by algorithms, scoring systems, and the lack of available data. This basic platform helps to speed up clinical trials and reduce the failure rate of promising medication candidates. SBDD has the potential to become a unique, dependable, and efficient drug design technique in the future.

The global computer-aided drug discovery market is segmented on the basis of type, therapeutic area, end-user, and region. By type, the market is classified into structure-based drug design (SBDD), ligand-based drug design (LBDD), and sequence-based approaches. By therapeutic area, the analysis has been divided into oncology, neurology, cardiovascular disease, respiratory disease, diabetes, and others. By end-user, the market has been divided into pharmaceutical companies, biotechnology companies, and research laboratories. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players profiled in this report include BOCSCI Inc., Bioduro-Sundia, Schrödinger, Inc., Aragen Life Sciences Pvt. Ltd., Aris Pharmaceuticals, Inc, Charles River Laboratories, Bayer AG, AstraZeneca, and Albany Molecular Research Inc. (AMRI).

The report focuses on the global computer-aided drug discovery market trends and the major products & applications, where computer-aided drug discovery is deployed. It further highlights numerous factors that influence the global computer-aided drug discovery market growth, such as forecast, trends, drivers, restraints, opportunities, and roles of different key players that shape the market. The report focuses on Computer-aided drug discovery market analysis, computer-aided drug discovery market share, and computer-aided drug discovery market opportunities in various countries, presenting data in terms of value. The revenue is calculated by proliferating the volume by region-specific prices, considering the region-wise differentiated prices.

IMPACT OF COVID-19 ON THE GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET

• The pandemic has had a negative impact on almost every industry segment in various ways, including supply chain disruptions and product delays. The global computer-aided drug discovery (CADD) market, on the other hand, has seen a positive impact throughout the COVID-19 pandemic.
• Computational technologies, specifically computer-aided virtual screening and molecular modelling, can play an important role in understanding the structural aspects of multiple coronavirus molecular targets and identifying novel lead molecules. In addition, research institutes and pharmaceutical and biotechnology firms are stepping up their efforts to combat a global pandemic. For example, in May 2021, researchers at Stony Brook University's Laufer Center, a hub for research in Physical and Quantitative Biology, announced to use computing therapeutics to discover chemicals that activate or inhibit viral molecules. This research is expected to accelerate drug discovery industry for coronavirus treatment.

Key Findings of the Study

• On the basis of type, the structure-based drug design segment emerged as the global leader in 2021 and is anticipated to be the largest market during the forecast period.
• On the basis of therapeutic area, the oncology segment emerged as the global leader in 2021 and is anticipated to be the largest market during the forecast period.
• On the basis of end user, the pharmaceutical companies segment emerged as the global leader in 2021 and is anticipated to be the largest market during the forecast period.
• On the basis of region, Asia-Pacific is projected to have the fastest growing market during the forecast period.